Presseaussendungen zu "Bachner"
609 AussendungenORF III am Donnerstag: „Die Tafelrunde“-Premiere aus dem Orpheum Graz, „Land der Berge“-Doppel im Trentino
Außerdem: Konzert „Starke Stimmen – Starke Frauen“ zum Weltfrauentag, „ORF III AKTUELL“
ORF-TV-Schwerpunkt zum Weltfrauentag 2022
Mit Dokus, Reportagen, Magazinen, Spielfilmen und Imagekampagne #keinwitz
Offener Brief der Musikschaffenden an den Bundeskanzler und die zuständigen Minister
Urheberrechtsgesetznovelle 2021: Musikschaffende fordern faire und angemessene Vergütung bei allen Verwertungen ihrer Leistungen im Internet
Wegovy(TM) Demonstrated Significant and Sustained Weight Loss in Two-Year Study in Adults With Obesity
* The STEP 5 trial demonstrated an average weight loss of 15.2% with Wegovy(TM) at 104-weeks when used with a reduced calorie meal plan and increased physical activity vs. 2.6% with placebo
Das sind die besten Hochbauer Österreichs 2021
Kilian Lupinski aus der Steiermark hat den Bundeswettbewerb der Hochbauer 2021 für sich entschieden.
Semaglutide in people with obesity: boosts wellbeing and ability to perform daily physical activities
Novo Nordisk today announced new results from the STEP phase 3a clinical trial programme, demonstrating potential benefits beyond weight loss for people with obesity being treated with semaglutide 2.4 mg.
Saxenda® recommended for approval by European Medicines Agency committee for the treatment of obesity in adolescents aged 12-17 years
Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has recommended that the use of Saxenda® is expanded for the treatment …
Adults with obesity treated with semaglutide 2.4 mg achieved and maintained a significant amount of weight loss in a 68-week trial
Data presented at ENDO 2021 demonstrate clinically relevant weight loss, without weight regain, in people treated with semaglutide 2.4 mg vs placebo in combination with lifestyle intervention.
Nicht mehr das Billigste vom Billigsten: Medizinprodukte-Branche fordert neue Beschaffungskriterien
Wien, 28. September 2020 – Die Corona-Pandemie hat die Medizinprodukte-Branche schlagartig in den Fokus der politischen Diskussion gerückt.
Das österreichische Gesundheitswesen – Das Forum Spital 2019 nennt das Sorgenkind beim Namen
Das imh Forum Spital 2019 in Mauerbach bei Wien thematisierte Gesundheitsreformen, Kassenzusammenlegungen, Finanzierungsfragen und Patiententourismus zwischen Fachkräftemangel im Gesundheitswesen und der …
Oral semaglutide demonstrated cardiovascular safety in people with type 2 diabetes and established cardiovascular disease or high cardiovascular risk in PIONEER 6 trial
Novo Nordisk today announced that the PIONEER 6 trial achieved its primary endpoint by demonstrating non-inferiority of major adverse cardiovascular events (MACE) with oral semaglutide compared with …
Oral semaglutide showed superior reductions in blood sugar vs Jardiance® and non-inferior blood sugar reductions vs Victoza® in adults with type 2 diabetes at 26 weeks
Findings presented today from two phase 3a clinical trials evaluated oral semaglutide 14 mg vs Jardiance® (empagliflozin 25 mg) in PIONEER 2 and oral semaglutide 14 mg versus Victoza® (liraglutide 1.8 mg) …
Konzertveranstaltungen in Niederösterreich
Vom Max Brand Ensemble bis zur Big Band Pfaffstätten
Oral semaglutide 7 mg and 14 mg doses showed superior reductions in blood sugar and weight compared to sitagliptin at 26 weeks in data presented at ENDO
Oral semaglutide 7 mg and 14 mg demonstrated superior HbA1c and body weight reductions compared to Januvia® (sitagliptin 100 mg).
